Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MST1R | Q04912 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436225 | 1.00 | IDO1 (0.40) | IDO1TDO2ALDH1A1ADRB2KDR | |
| SCHEMBL6328087 | 0.94 | IDO1 (0.41) | IDO1TDO2ALDH1A1KDRGAA | |
| SCHEMBL6328091 | 0.94 | IDO1 (0.41) | IDO1TDO2ALDH1A1KDRGAA | |
| SCHEMBL6320093 | 0.91 | ADRA2C (0.40) | IDO1TDO2ALDH1A1ADRB2KDR | |
| SCHEMBL6320087 | 0.91 | ADRA2C (0.40) | IDO1TDO2ALDH1A1ADRB2KDR | |
| SCHEMBL6319638 | 0.91 | MEN1 (0.38) | IDO1TDO2ALDH1A1ADRB2KDR | |
| SCHEMBL6319632 | 0.91 | MEN1 (0.38) | IDO1TDO2ALDH1A1ADRB2KDR | |
| SCHEMBL6321023 | 0.90 | IDO1 (0.39) | IDO1TDO2ALDH1A1ADRB2KDR | |
| SCHEMBL6319358 | 0.90 | IDO1 (0.39) | IDO1TDO2ALDH1A1ADRB2KDR | |
| SCHEMBL6322707 | 0.88 | IDO1 (0.42) | IDO1TDO2ALDH1A1KDRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2826480-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | Boehringer Ingelheim International GmbH (DE) | 2015-01-21 | — | — | EP | claimed |
| EP-2409705-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-25 | — | — | EP | claimed |
| EP-2361626-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-31 | — | — | EP | claimed |
| EP-2359829-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-24 | — | — | EP | claimed |
| JP-4701159-B2 | — | — | 2011-06-15 | — | — | JP | claimed |
| EP-2281561-A2 | Use of LCK inhibitors for treatment of immunologic diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-02-09 | — | — | EP | claimed |
| US-20090306104-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | claimed |
| US-20090087405-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-02 | — | — | US | claimed |
| US-20080254040-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | claimed |
| JP-2006524634-A | — | — | 2006-11-02 | — | — | JP | claimed |
| EP-1622619-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| EP-1530466-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | Boehringer Ingelheim Pharma KG (DE) | 2005-05-18 | — | — | EP | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| US-20040204458-A1 | Use of Lck inhibitors for treatment of immunologic diseases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-14 | — | — | US | claimed |
| WO-2004017948-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | claimed |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-24 | — | — | US | disclosed |
| EP-2826480-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | Boehringer Ingelheim International GmbH (DE) | 2015-01-21 | — | — | EP | disclosed |
| WO-2004017948-A2 | USE OF LCK INHIBITOR FOR TREATMENT OF IMMUNOLOGIC DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080254040-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS OR ANGIOGENESIS | BAX, BCL2, CXCL12 | IDO1 3148/4885TDO2 4729/4885ALDH1A1 2154/4885 |
| US-20150265610-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BAX, BCL2, VEGFA | IDO1 3030/4885TDO2 4733/4885ALDH1A1 2021/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | IDO1 3148/4885TDO2 4729/4885ALDH1A1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.